The prognosis of patients with human high-grade gliomas (HGGs) remains dismal despite major advances in their management, due mainly to the high resistance of these infiltrative tumor cells to programmed cell death (PCD). Most therapeutic strategies for HGGs are aimed to maximize PCD type I, apoptosis or type II, autophagy. These are predominantly distinctive processes, but many studies suggest a cross-talk between the two. A better understanding of the link between PCD types I and II might allow development of more effective therapies for HGGs. In this study, we examined whether there is a common upstream signaling event responsible for both apoptotic and autophagic PCD using 3 chemotherapeutic agents in human HGG cells. Our study shows that each agent caused a significant decrease in cell viability in each of the HGG cell lines tested. The increase rate of apoptosis and autophagy varied among cell lines and chemotherapeutic agents used. Increased expression of cytidine-cytidine-adenosine-adenosine-thymidine (C)/ enhancer binding protein (EBP) homologous transcription factor C/EBP homologous protein (CHOP)/ growth arrest and DNA damage-inducible gene 153 (GADD153) was documented after use of either proautophagic or pro-apoptotic agents. The involvement of CHOP/GADD153 in both type I and type II PCD was confirmed by overexpression and gene-silencing studies. Gene silencing by small-interfering RNAmediated CHOP/GADD153 resulted in increased cell viability, decreased upregulation of microtubule-associated protein light-chain 3 ′ type II (LC3II) and cleaved caspase-3, and inhibition of apoptosis and autophagy. Exogenous expression of CHOP/GADD153 triggered apoptosis and autophagy in the absence of other stimuli. The clinical significance of these findings was supported by the evidence that celecoxib, a nonsteroidal anti-inflammatory drug known to induce GADD153-mediated apoptosis, strongly increases both type I and type II PCD in HGG cells when combined with another inducer of GADD153. These data suggest that CHOP/ GADD153 should be investigated as a novel targetable signaling step to improve therapies for HGGs.
The prognosis of patients with human high-grade gliomas (HGGs) remains dismal despite major advances in their management, due mainly to the high resistance of these infiltrative tumor cells to programmed cell death (PCD). Most therapeutic strategies for HGGs are aimed to maximize PCD type I, apoptosis or type II, autophagy. These are predominantly distinctive processes, but many studies suggest a cross-talk between the two. A better understanding of the link between PCD types I and II might allow development of more effective therapies for HGGs. In this study, we examined whether there is a common upstream signaling event responsible for both apoptotic and autophagic PCD using 3 chemotherapeutic agents in human HGG cells. Our study shows that each agent caused a significant decrease in cell viability in each of the HGG cell lines tested. The increase rate of apoptosis and autophagy varied among cell lines and chemotherapeutic agents used. Increased expression of cytidine-cytidine-adenosine-adenosine-thymidine (C)/ enhancer binding protein (EBP) homologous transcription factor C/EBP homologous protein (CHOP)/ growth arrest and DNA damage-inducible gene 153 (GADD153) was documented after use of either proautophagic or pro-apoptotic agents. The involvement of CHOP/GADD153 in both type I and type II PCD was confirmed by overexpression and gene-silencing studies. Gene silencing by small-interfering RNAmediated CHOP/GADD153 resulted in increased cell viability, decreased upregulation of microtubule-associated protein light-chain 3 ′ type II (LC3II) and cleaved caspase-3, and inhibition of apoptosis and autophagy. Exogenous expression of CHOP/GADD153 triggered apoptosis and autophagy in the absence of other stimuli. The clinical significance of these findings was supported by the evidence that celecoxib, a nonsteroidal anti-inflammatory drug known to induce GADD153-mediated apoptosis, strongly increases both type I and type II PCD in HGG cells when combined with another inducer of GADD153. These data suggest that CHOP/ GADD153 should be investigated as a novel targetable signaling step to improve therapies for HGGs.
Keywords: apoptosis, autophagy, CHOP/GADD153, cell viability, gliomas. High-grade gliomas (HGGs), the most frequent types of gliomas, are associated with poor prognosis. Among these, glioblastoma multiforme (GBM), accounting for 50% of gliomas, is associated with a 5-year survival rate of less than 5% and a median survival rate of approximately 14 months, even after use of aggressive surgical tumor resection and postoperative radiation therapy combined with temozolomide (TMZ) chemotherapy is used.
2 This is due mainly to high resistance of these infiltrative tumor cells to programmed cell death (PCD).
HGG cells show only partial sensitivity to therapies that induce apoptosis, i.e., PCD type I. 3 -6 Recent studies indicate that HGG cells are more sensitive to treatments that induce autophagy, i.e., PCD type II. 5, 6 A variety of chemical and physical treatments, including ionizing radiation (IR); 7 arsenic trioxide, As 2 O 3 (ATO); 8, 9 TMZ; 10 and many others, have been reported to induce autophagy in vitro and in vivo in HGG cells. Additionally, some chemotherapeutics have both pro-apoptotic and pro-autophagic actions. In particular, TMZ, the oral alkylating agent currently considered the standard of care for patients with HGG, has been shown to exert its cytotoxicity by inducing both apoptosis and autophagy. 6,10 -15 Autophagy and apoptosis cause PCD by two predominantly distinct pathways. 5, 16, 17 Recent studies, however, have suggested a cross-talk between them. 18, 19 Moretti et al. 19 summarized the mechanisms that might connect these two pathways in the setting of IR. IR has been shown to activate unfolded protein response (UPR), which triggers an endoplasmic reticulum (ER) stress response. The UPR consists of a set of adaptive pathways that are triggered by disturbances in normal function of the ER, leading to the production of misfolded proteins. The UPR alleviates ER stress by arresting general translation, upregulation of chaperones and folding enzymes, and degradation of misfolded proteins. 20 When the whole ER system is overloaded with misfolded proteins, cells will undergo cell death, typically via apoptosis. 21 -23 ER stress can also induce autophagic cell death; however, the molecular mechanisms behind it are still not fully elucidated. 24, 25 A major UPR target is the induction of the glucose-regulated protein (GRP)-78/binding protein (BiP), which plays an important role in protein folding and assembly, targeting misfolded proteins for degradation, ER Ca 2+ binding, and control of the activation of transmembrane ER stress sensors. 26 Thus, GRP-78 represents a prosurvival arm of the UPR. On the other hand, the cytidine-cytidine-adenosine-adenosine-thymidine (C)/enhancer binding protein (EBP) homologous transcription factor C/EBP homologous protein (CHOP)/growth arrest and DNA damage -inducible gene 153 (GADD153) is one of the critical executioners of the pro-apoptotic arm of the UPR. 27 Signals are induced from CHOP that the cell is experiencing ER stress and hence initiating PCD. Microarray studies revealed that CHOP is one of the most highly inducible genes during ER stress. 28 Overexpression of CHOP and micro-injection of CHOP protein have been reported to lead to cell-cycle arrest and cell apoptosis. 29, 30 In our study, we test the hypothesis that in the presence of non-IR -induced ER stress, there is an upstream common signal that links autophagy and apoptosis. Our current experiments show that CHOP/GADD153 serves as an important link between PCD type I and type II in the presence of non-IR -induced ER stress in human HGGs. Finally, to show the potential clinical significance of our results, we investigated the effects of combining two ER stress -inducing agents on HGG PCD. We chose celecoxib (CXB), a nonsteroidal antiinflammatory drug and COX-2 inhibitor exhibiting a promising chemopreventive activity in experimental animal models of colon cancer and in clinical trials.
-33

Materials and Methods
Cell Lines, Cultures, and Chemotherapeutic Agents
The human HGG cell lines U87, A172, and T98G used for these in vitro experiments were obtained from the American Type Culture Collection. Cells were propagated in monolayer and cultured in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal calf serum in a 378C incubator supplemented with 5% CO 2 . TMZ was supplied by Schering-Plough, dissolved in dimethyl sulfoxide (DMSO), kept in 50-mM stock solution, and used at a concentration of 100 mmol/L, according to our previous work. 10 ATO (MP Biomedicals) was used at a concentration of 4 mM in all experiments, according to our previous work. 8, 9 Cisplatin (CDDP) (Enzo Life Sciences) was used at a concentration of 5 mg/mL in all experiments. 34 Recombinant human DNA damage -inducible transcript 3/GADD153 (Creative BioMart) was used at a concentration of 1 mg/mL. CXB (Toronto Research Chemicals) was used at concentrations of 10 and 20 mM.
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Cell Viability Assay
Cell viability was measured by a 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assay kit (Chemicon International). Cells were seeded in 96-well tissue culture plates (1.0 × 10 3 cells per well) 24 h prior to treatment. Seventy-two hours after treatment, the medium was removed, and fresh medium containing 0.5 mg/mL MTT was added to each well. The cells were incubated at 378C for 4 h, and then an equal volume of color development solution (0.04 N HCl in isopropanol) was added to each well and mixed thoroughly. The optical density from the plates was read on a micro plate reader at 570 nm.
Apoptosis and Inhibition Assay
Fluorescence-activated cell sorting (FACS) analysis was used to quantify apoptotic cells after treatment, following labeling with Annexin V-Phycoerythrin (PE) to detect early apoptotic cells and vital dye 7-Amino-Actinomycin (7AAD) to detect late apoptotic and necrotic cells, using an Annexin V kit (BD Biosciences) following manufacturer instructions. Briefly, 2 × 10 5 HGG cells were seeded in a 6-well plate 24 h prior to treatment. The following day, cells were treated as indicated in the cell viability assay section of this paper, and 72 h later were collected for staining. Gating with appropriate measurement of forward and side scatter was used to exclude cell debris and cell aggregates from the sorting; 5000 to 10 000 cells were counted per analysis. Data from flow cytometry (Becton Dickinson) were further analyzed using the FlowJo software (Treestar). Apoptosis was inhibited with a pan-caspase inhibitor, Z-DEVD-FMK (Z-VAD(OMe)-FMK) (R&D Systems) solubilized in DMSO following manufacturer instructions. Cells were pretreated with 50 mM of Z-DEVD-FMK for 1 h before treatment with each chemotherapeutic. Cell viability was measured by MTT assay 72 h later, as described above.
Autophagy and Inhibition Assay
Autophagy is the process of sequestrating cytoplasmic proteins into the lytic component and is characterized by the formation of acidic vesicular organelles. To detect and quantify these 72 h after treatment, we performed vital staining with acridine orange (AO; Invitrogen), as previously described. 10 Briefly, cells were stained with AO at a final concentration of 1 mg/ mL for a period of 15 min, removed from the plate with trypsin -ethylenediaminetetraacetic acid, and collected in phenol red-free growth medium. Green (510-530 nm) and red (.650 nm) fluorescence emission from 10 4 cells illuminated with blue (488 nm) excitation light was measured with FACSCalibur using Flowjo software. To inhibit autophagy, 1 mM 3-methyladenine (Sigma-Aldrich) was added 24 h after treatment with each chemotherapeutic. 10 Cell viability was measured by MTT assay 72 h after chemotherapeutic treatment, as described above.
Western Blot Analysis
Briefly, for western blotting experiments, cells were harvested in radioimmunoprecipitation assay buffer (1% Nonidet P-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS] in phosphate buffered saline) containing a protease inhibitor cocktail (Roche), 50 mM NaF, and 1 mM Na3VO4, homogenized and centrifuged at 12 000 rpm for 10 min at 48C. The supernatant was used as total cell lysate. Protein lysates (30 -50 mg) were denatured in 2% SDS, 10 mM dithiothreitol, 60 mM Tris-HCl (pH 6.8), and 0.1% bromophenol blue and loaded onto a 12% polyacrylamide/SDS gel (National Diagnostics). The separated proteins were then transferred by electroblot (80 mA, 2 h) onto a polyvinylidene fluoride membrane (Roche). The membrane was blocked for 1 h at room temperature (rT) in 0.1 M Tris-HCl (pH 7.6), 1.37 M NaCl, 0.1% Tween 20 (TBS-T) containing 5% nonfat dry milk and incubated overnight at 48C in TBS-T containing the primary antibody. The membrane was washed in TBS-T, incubated with the secondary antibody conjugated to horseradish peroxidase for 1 h at rT, and then washed in TBS-T. An enhanced chemiluminescence nonradioactive detection system (Amersham Pharmacia Biotech) was utilized to detect the antibody-protein complexes by exposure of the membrane to an X-ray film.
The following primary antibodies were used: rabbit polyclonal LC3B (1:1000) and rabbit polyclonal caspase-3 (1:1000) (Cell Signaling Technology), mouse monoclonal GADD153 (1:500) and goat polyclonal GRP-78 (1:500) (Santa Cruz Biotechnology), and mouse monoclonal actin (1:1000) (Millipore). Cell lysates for the detection of LC3, caspase-3, and GADD153 were prepared 48 h after chemotherapeutic treatment. For GRP-78 detection, cell lysates prepared at 10 h after chemotherapeutic treatment were used.
Transfection with siRNA CHOP/GADD153 small interfering RNA (siRNA) was purchased from Santa Cruz Biotechnology. The transfection of siRNA was performed according to manufacturer instructions.
Transfection of CHOP/GADD153 Expression Vector
HGG cells were plated in 6-well plates at a density of 3 × 10 5 cells/mL and incubated at 378C in a 5% CO 2 atmosphere. Cells were transfected with the expression plasmid CHOP/pCMV6-XL5 or empty plasmids (pCMV6-XL5) using Lipofectamine 2000 reagent (Invitrogen). The CHOP expression plasmid CHOP/ pCMV6-XL5 was purchased from Origene Technologies. 36 Cells were harvested at 72 h after transfection for western blot and FACS analyses.
Statistical Analysis
All studies were repeated 3 times using triplicate samples for cell counting analysis. The statistical significance of the experimental results was evaluated using unpaired Student's t-tests. The data are expressed as means + standard deviations and are considered significant when P , .05.
Results
TMZ, ATO, and CDDP Induce Decreased Cell Viability and Increased Apoptosis and Autophagy in Human HGGs
The pro-apoptotic and pro-autophagic effects of TMZ (100 mM), ATO (4 mM), and CDDP (5 mg/mL) were assessed on 3 HGG cell lines: U87, A172, and T98G. Each treatment caused a significant decrease in cell viability in each of the tested cell lines (P , .05, Student's t-test) compared with the nontreated controls independent of p53 status (Fig. 1A) . CDDP had the most profound effects in all cell lines.
A significant increase in apoptotic rate was seen in all 3 cell lines after treatment with ATO and CDDP compared with control cells (P , .05). TMZ caused a significant increase in apoptotic rate in T98G and A172 cells (Fig. 1B) . CDDP had the most robust pro-apoptotic effect in all cell lines.
To explore the possible induction of autophagy, we quantified the presence of acidic vesicular organelles, which are characteristic of this process and can be detected by flow cytometry with AO staining. A significant increase in autophagy rate (P , .05) was found in all 3 cell lines after treatment with each of the 3 agents (Fig. 1C) .
To confirm the presence of apoptosis and autophagy signaling and the induction of ER stress, western blotting was used to detect GRP-78/BiP, an ER stress marker; microtubule-associated protein light-chain 3 ′ type II (LC3II; autophagy); and cleaved caspase-3 (apoptosis). These results confirmed the presence of expected signaling in U87 and T98G cells after each treatment (Fig. 2) . The activation of CHOP/GADD153 was seen after each treatment, suggesting that it could be a linking signal for both apoptosis and autophagy.
Effects of Inhibition of Apoptosis or Autophagy on Cell Viability After TMZ, ATO, or CDDP Treatment of Human HGGs
To determine the predominant pathway of PCD after treatment with each chemotherapeutic agent, we conducted inhibition experiments and assessed cell viability. Apoptosis was inhibited by the pan-caspase inhibitor Z-VAD-FMK and autophagy by 3-methyladenine, an autophagy inhibitor acting on the activity of phosphatidyl-inositol-3 kinase with halted formation of autophagosome and autophagic vacuoles. Lack of significant change in cell viability after blockage of apoptosis (Fig. 3A) or autophagy (Fig. 3B ) was seen only after treatment with ATO in U87 HGG cells. After treatment with CDDP, inhibition of apoptosis caused significant increased viability. However, inhibition of autophagy did not have any significant effect. On the contrary, after treatment with TMZ, inhibition of autophagy caused significant increased viability. However, inhibition of apoptosis did not have any significant effect. These results confirm that TMZ causes cell demise mostly by autophagy and CDDP mostly by apoptosis. Similar effects were seen in T98G HGG cells (data not shown).
Together, these results support the concept that the cytopathic effects of ATO on human HGGs are caused by both apoptosis and autophagy. Thus, ATO was used in our next experiments to test our hypothesis that CHOP/GADD153 serves as an upstream link between apoptosis and autophagy.
CHOP/GADD153 Links Apoptosis and Autophagy in Human HGGs
To elucidate the potential role of CHOP/GADD153 in autophagic and apoptotic PCD in human HGGs, we performed western blot analysis following silencing of CHOP/GADD153 by siRNA (Fig. 4) . Inhibition of CHOP/GADD153 resulted in decreased expression of apoptosis (cleaved caspase-3) and autophagy (LC3II) markers in U87 and T98G HGG cells. These results suggest that CHOP/GADD153 serves as an upstream link between apoptosis and autophagy.
To confirm the role of CHOP/GADD153 in linking PCD types I and II, we performed cell viability assays and quantification of autophagy and apoptosis after siRNA blockage of CHOP/GADD153. Cell viability was significantly increased after CHOP/GADD153 blockage in U87 (Fig. 5A) and T98G (Fig. 5B ) HGG cells. Apoptosis and autophagy were also significantly reduced after CHOP/GADD153 silencing in both HGG cells. 
Overexpression of CHOP/GADD153 Decreases Cell Viability by Inducing Apoptosis and Autophagy in Human HGGs
To substantiate the significance of GADD153 on apoptosis, autophagy, and cell viability, an expression plasmid containing the full-length complementary DNA of human GADD153 was transiently transfected into HGG cells. GADD153 overexpression significantly decreased cell viability by inducing apoptotic as well as autophagic cell death (Fig. 6) . Overexpression of GADD153 and LC3 and cleavage of caspase-3 were confirmed by western blot analysis ( Fig. 6D and H 
Combination of ATO with CXB Significantly Enhances PCD in Human HGG Cells by Inducing ER Stress
In view of the differential ER stress -inducing effects generated by ATO and CXB, 30,37,38 we next examined the effects of the combination of these stressors on human HGG cell growth and survival. We combined ATO with CXB at subtoxic concentration (Fig. 7) . Combined ATO and CXB treatment resulted in significant decreased cell viability, with additive effects in U87 cells, whereas treatment with CXB alone did not. To elucidate the basis for this decrease, apoptosis and autophagy were analyzed. Combined ATO and CXB treatment resulted in a significant increase in autophagy and apoptosis in both U87 and T98G human HGG cells, whereas individual drugs did not. We next investigated the potential contribution of ER stress to the above-presented combination drug effects. U87 and T98G cells were treated with ATO and CXB as single treatment and in combination, and levels of CHOP (ER stress), and apoptosis and autophagy markers (cleaved caspase-3 and LC3II) were analyzed. ER stress protein CHOP was strongly elevated by combination treatments of ATO and CXB ( Fig. 7G and H) in both U87 and T98G cells compared with single drug treatment. The apoptosis executioner caspase-3 and autophagy marker LC3II were more strongly activated by combination drug treatments than by individual drug treatment. Taken together, these results indicate that ATO, when combined with CXB, caused stronger ER stress induction and increased PCD compared with single drug treatment.
Discussion
In this study we confirm the pro-apoptotic and pro-autophagic effects of TMZ, ATO, and CDDP on human HGG cells. We show that each treatment induces ER stress and increases expression of CHOP/ GADD153. Additionally, we show that GADD153 is critical for ATO-induced apoptosis and autophagy of human HGG cells. Two lines of evidence support this conclusion. First, silencing of the GADD153 gene by siRNA blocked ATO-induced apoptosis and autophagy in HGG cells. Second, increased concentration of GADD153 by adding ectopic recombinant protein or overexpression of CHOP/GADD153 complementary DNA was sufficient to induce decreased cell viability by inducing apoptosis and autophagy in HGG cells in the absence of additional apoptotic/autophagy stimuli. Finally, we show that combining 2 known ER stressors, ATO and CXB, strongly increases PCD types I and II in HGG cells. These results suggest that CHOP/ GADD153 plays an important role in linking non-IR ER stress -induced apoptosis and autophagy in HGGs. This link should be further investigated as a potential target for adjuvant therapy of human HGGs, which remains a therapeutic challenge. 2 This is due mainly to the high resistance of these infiltrative tumor cells to apoptosis, i.e., PCD type I. Recent evidence shows that HGG cells might be more sensitive to autophagy, i.e., PCD type II. 5, 6 Since both IR and TMZ have been shown to induce apoptosis and autophagy, 7, 10, 11, 14, 19 it is reasonable to postulate that if the upstream signal(s) linking PCD type I and type II is identified, this could then be targeted to potentiate PCD. In this study we confirmed that each of the three chemotherapy agents tested (ATO, TMZ, and CDDP) induced decreased cell viability by causing apoptosis and autophagy. When apoptosis or autophagy was blocked, however, a lack of significant change in cell viability was seen after treatment with only ATO, indicating that cytotoxic effects of ATO on human HGGs are caused by both apoptosis and autophagy. With TMZ treatment there was a significant effect on cell viability only after blocking autophagy, and with CDDP only after blocking apoptosis. These results support the concept that TMZ causes tumor cell demise mostly by autophagy, as we and others previously reported. 10, 11 Conversely, the primary cytopathic effect of CDDP is via apoptosis. 34, 39 Recent studies highlight the complex interplay between apoptosis and autophagy. When the ER is subjected to stress, both apoptosis and autophagy are affected. The link between these 2 PCDs is, however, still not fully characterized. To identify such link in this study, we used ATO as a non-IR ER stress inducer known to cause apoptosis and autophagy. We tested the hypothesis that CHOP/GADD153 serves as an upstream link for apoptosis and autophagy in HGGs. CHOP/GADD153 is a leucine zipper transcription factor present at low levels under normal conditions but highly upregulated in response to a variety of stresses and agents, especially ER stress. 40, 41 In tumor cells, the GADD153 promoter has been found to be responsive to a broad spectrum of genotoxic agents. The CHOP gene can be activated through the ER stress response elements in response to cellular stress, 42, 43 amino acid response elements in response to amino acid starvation, 44 -46 and the C/EBP-activating transcription factor composite site, a part of the amino acid response elements -1, in response to phosphatidylcholine depletion and ER stress. 47 Recently, Pyrko et al. 40 showed induction of CHOP in glioma cell lines following treatment with TMZ. Induction of CHOP/GADD153 after treatment with ATO has been shown previously in neutrophils in glioma, pancreatic, colorectal, and breast cancers. 37, 48, 49 CDDP has been shown to induce GADD153 in head/neck and ovarian cancer, xenografted melanoma, and squamous cell carcinoma. 50 -52 In our study, we showed robust increased expression of CHOP/GADD153 after treatment with TMZ, ATO, or CDDP in U87 and T98G HGG cells. Additionally, suppression of CHOP/GADD153 by siRNA caused a significant decrease in apoptotic and autophagic rates in HGG cells, as indicated by decreased expressions of cleaved caspase-3 and LC3II and decreased formation of acidic vesicular organelles. These findings suggest that CHOP/GADD153 plays a key role in linking non-IR ER stress -induced apoptosis and autophagy. GADD153 expression has been associated with apoptosis in response to a number of stress stimuli, including anticancer agents, retinoic acid, and nutrient deprivation. 45,53 -56 In addition to its function as a transcription factor, GADD153 has been shown to mediate apoptosis through a nontranscriptional pathway. 53, 57 Recent studies demonstrated that knockdown of CHOP using CHOP-specific siRNA significantly suppressed apoptosis induction and activation of effector caspase-3. 48,58 -60 Recent studies also suggest that UPR-triggered CHOP promotes the activation of the autophagic process through the transcriptional control of ATG5 and LC3B. 61 A recent study by Santos-Gomez et al. 62 showed that dopamine treatment triggers autophagy in neuroblastoma cells, which is associated with GADD153 induction. Additionally, Ke et al. 61 recently showed that knockdown of CHOP by siRNA duplexes greatly downregulated the expression of LC3B-II. Additional studies are needed to elucidate the mechanism(s) of CHOP-regulated expression of LC3.
Among all chemotherapeutic agents available, platinum-based drugs, such as CDDP and carboplatin, have played the most important role in the treatment of solid tumors. 63 The major mechanism underlying CDDP activity is the induction of DNA damage and induction of apoptosis. 39 Its use as adjuvant treatment of HGGs has been limited by its toxicity after systemic administration and poor brain penetration due to the blood -brain barrier. Recently, interest in this drug has resurged, as it has been shown to induce autophagy in the U251 HGG cell line. 64 Additionally, it has been shown that it can be delivered intraparenchymally by convection-enhanced delivery, with increased survival in F98 glioma-bearing rats. 65 Our study confirms the pro-apoptotic and pro-autophagic effects of CDDP. These occur by induction of ER stress and activation of CHOP/GADD153 signaling. However, since suppression of CHOP/GADD153 by siRNA after CDDP results in a significant decrease in only apoptotic rate (data not shown), and only treatment with a pan-caspase inhibitor results in significant increased viability, as shown in Fig. 3 , we suggest that most of the cell demise after CDDP occurs secondary to PCD type I. These results taken together with those reported above support the concept that although CHOP/ GADD153 plays a key role in linking non-IR ER stress -induced apoptosis and autophagy, additional signaling pathways might be involved. Further studies to clarify this aspect are needed.
In the present study, we show that overexpression of CHOP/GADD153 resulted in decreased cell viability via apoptosis and autophagy in human HGG cells in the absence of additional apoptotic/autophagy stimuli. This observation suggests that CHOP itself may be more efficient to sensitize cells to other ER stress agents. Indeed, we showed that when ATO and CXB were combined, enhanced cytotoxicity occurred. These data provide the evidence that the combination of 2 ER stress inducers, at clinically achievable concentrations, exerts greatly increased cytotoxicity on HGG cells. Each drug can independently induce ER stress, 37, 38 and their combination further aggravates ER stress to the point where the protective components of this system are overwhelmed and the pro-apoptotic/pro-autophagic constituents gain dominance to PCD. Although further in vivo animal studies are required to support the clinical application of ATO/CXB as a co-treatment, with the potential of CXB to bypass the blood -brain barrier, 66 our findings support clinical translation of combined ATO and CXB in HGG patients.
